SSA
AUPH icon

Sierra Summit Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Sierra Summit Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-60,813
Closed -$901K – 193
2026
Q1 		$901K Buy
+60,813
New +$889K 0.13% 117
2024
Q1 		– Sell
-22,436
Closed -$202K – 152
2023
Q4 		$202K Buy
+22,436
New +$185K 0.06% 188

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sierra Summit Advisors's AUPH Position: Q2 2026 in Review

Sierra Summit Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2026, closing a stake of 60,813 shares — an estimated $901K sold.

Sierra Summit Advisors first reported a position in AUPH in Q4 2023 and held it in 2 quarters. The position peaked at $901K in Q1 2026. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Sierra Summit Advisors reported no remaining Aurinia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Sierra Summit Advisors sold 60,813 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $901K.
  • Sierra Summit Advisors first reported a position in Aurinia Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Sierra Summit Advisors's Aurinia Pharmaceuticals position peaked at $901K in Q1 2026.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Sierra Summit Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.